Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 4, 2003, Pages 1075-1083

  Pauwels, Bea ^a   Korst, Annelies E C ^a   Pattyn, Greet G O ^a   Lambrechts, Hilde A J ^a   Van Bockstaele, Dirk R ^a   Vermeulen, Katrien ^a   Lenjou, Marc ^a   De Pooter, Christel M J ^b   Vermorken, Jan B ^a   Lardon, Filip ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SINT AUGUSTINUS HOSPITAL   (Belgium)

Author keywords

Cell cycle; Gemcitabine; Radiosensitization; Radiotherapy

Indexed keywords

CELLS; ONCOLOGY; TUMORS;

RADIOSENSITIVITY;

RADIOTHERAPY;

GEMCITABINE;

ARTICLE; BLADDER CANCER; CANCER CELL; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE S PHASE; CHRONOLOGY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LUNG CANCER; PRIORITY JOURNAL; RADIOSENSITIZATION;

EID: 0142217877     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)01443-3     Document Type: Article

References (44)

1. Storniolo A.M., Allerheiligen S.R.B., Pearce H. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol. 24:1997;2-7.
2. Peters G.J., Ruiz van Haperen V.W.T., Bergman A.M., et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol. 23:1996;16-24.
3. Latz D., Fleckenstein K., Eble M., et al. Radiosensitizing potential of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys. 41:1998;875-882.
4. Doyle T.H., Mornex F., McKenna G. The clinical implications of gemcitabine radiosensitization. Clin Cancer Res. 7:2001;226-228.
5. Shewach D.S., Lawrence T.S. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs. 14:1996;257-263.
6. Lawrence T.S., Chang E.Y., Hahn T.M., et al. Radiosensitization of pancreatic cancer cells by 2′, 2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 34:1996;867-872.
7. Lawrence T.S., Eisbruch A., Shewach D.S. Gemcitabine-mediated radiosensitization. Semin Oncol. 24:1997;24-28.
8. Mose S., Karapetian M., Juling Pohlit L., et al. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Res. 20:2000;401-405.
9. Rosier J.F., Beauduin M., Bruniaux M., et al. The effect of 2′-2′ difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. Int J Radiat Biol. 75:1999;245-251.
10. Shewach D.S., Hahn T.M., Chang E., et al. Metabolism of 2′, 2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 54:1994;3218-3223.
11. Shewach D.S., Lawrence T.S. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol. 23:1996;65-71.
12. Joschko M.A., Webster L.K., Groves J., et al. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Invest. 5:1997;62-71.
13. Milas L., Fujii T., Hunter N., et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 59:1999;107-114.
14. Mason K.A., Milas L., Hunter N.R., et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys. 44:1999;1125-1135.
15. Eisbruch A., Shewach D.S., Bradford C.R., et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer A phase I trial and intracellular drug incorporation study. J Clin Oncol. 19:2001;792-799.
16. Pipas J.M., Mitchell S.E., Barth R.J., et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 50:2001;1317-1322.
17. Ikeda M., Okada S., Tokuuye K., et al. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer. 86:2002;1551-1554.
18. de Lange S.M., van Groeningen C.J., Meijer O.W.M., et al. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer. 38:2002;1212-1217.
19. Mohiuddin M., Kudrimou M., Regine W.F., et al. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy A phase I study. Cancer J. 8:2002;255-262.
20. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 19:2001;4202-4208.
21. Crane C.H., Janjan N.A., Evans D.B., et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol. 29:2001;9-18.
22. Trodella L., GrAnone P., Valente S., et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol. 20:2002;804-810.
23. Ostruszka L.J., Shewach D.S. The role of cell cycle progression in radiosensitization by 2′, 2′-difluoro-2′-deoxycytidine. Cancer Res. 60:2000;6080-6088.
24. Robinson B.W., Shewach D.S. Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clin Cancer Res. 7:2001;2581-2589.
25. Mose S., Class R., Weber H., et al. Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol. 26:2003;60-69.
26. Chen M., Hough A.M., Lawrence T.S. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol. 45:2000;369-374.
27. Lawrence T.S., Davis M.A., Hough A., et al. The role of apoptosis in 2′, 2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res. 7:2001;314-319.
28. Wachters FM, Kampinga HH, Van Putten JWG, et al. Gemcitabine selectively targets homologous recombination mediated DNA double strand break repair. Proc Am Assn Cancer Res 2002;43:740a.
29. Pauwels B., Korst A.E.C., De Pooter C.M.J., et al. The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro. Eur J Cancer. 39:2003;838-846.
30. Skehan P., Storeng R., Scudiero D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 82:1990;1107-1112.
31. Papazisis K.T., Geromichalos G.D., Dimitriadis K.A., et al. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods. 208:1997;151-158.
32. Pauwels B., Korst A.E.C., De Pooter C.M.J., et al. Comparison of the sulforhodamine B test and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol. 51:2003;221-226.
33. Vindelov L.L., Christensen I.J., Nissen N.I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 3:1983;323-327.
34. Fertil B., Dertinger H., Courdi A., et al. Mean inactivation dose A useful concept for intercomparison of human cell survival curves. Radiat Res. 99:1984;73-84.
35. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:1984;27-55.
36. Leonard C.E., Chan D.C., Chou T.C., et al. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. 56:1996;5198-5204.
37. Cappella P., Tomasoni D., Faretta M., et al. Cell cycle effects of gemcitabine. Int J Cancer. 93:2001;401-408.
38. Bandala E., Espinosa M., Maldonado V., et al. Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine. Biochem Pharmacol. 62:2001;13-19.
39. Tolis C., Peters G.J., Ferreira C.G., et al. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer. 35:1999;796-807.
40. Merlin T., Brandner G., Hess R.D. Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs. Int J Oncol. 13:1998;1007-1016.
41. Tang J.T., Yamazaki H., Inoue T., et al. Mitochondrial DNA influences radiation sensitivity and induction of apoptosis in human fibroblasts. Anticancer Res. 19:1999;4959-4964.
42. Sinclair W.K. Sensitivity to mitotic delay and stage in the cycle. Curr Top Radiat Res. 7:1972;323-327.
43. Tang H.Y., Davis M.A., Strickfaden S.M., et al. Influence of cell cycle phase on radiation-induced toxicity and DNA damage in human colon cancer (HT-29) and chinese hamster ovary cells. Radiat Res. 138:1997;S109-S112.
44. Terasima T, Tolmach LJ. Variation in several responses of HeLa cells to X-irradiation during the division cycle. Biophys J 1963;3:11-33.